Crohn's disease

【Product name】Putti, Envarsus, MODIGRAF, PROGRAF, Tacrolimus, ASTAGRAF

[English common name]Tacrolimus

[Chinese common name]Tacros

[English name]Big ring piperon, Taikelima

[Chinese other name]Macrocyclic melam, texley horse

[indications]
Tacrolimus Sustained Release Capsule: Prevents graft rejection after liver or kidney transplantation.
Tacrolimus injection:
1. Prevention of graft rejection after liver or kidney transplantation.
2. Treatment of graft rejection after liver or kidney transplantation using other immunosuppressive drugs.
Tacrolimus ointment: This product is suitable for patients with moderate to severe atopic dermatitis who are not suitable for traditional treatment due to potential risks, or who have not responded to traditional therapies or cannot tolerate traditional therapy, as short-term or intermittent long-term treatment. .
Tacrolimus capsule: Prevents graft rejection after liver or kidney transplantation.

【Dosage】
Tacrolimus Sustained Release Capsules:
1. Recommended starting dose for oral administration of Prograf in adults after surgery:
(1) For patients with liver transplantation, the initial oral dose should be 0.1-0.2 mg/kg per day by weight, taken orally twice, and started 6 hours after surgery.
(2) For kidney transplant patients, the initial oral dose should be 0.15-0.3 mg/kg per day by weight, divided into two orally, and the drug should be started within 24 hours after surgery.
2. Rejection that is ineffective against traditional immunosuppressive therapy:
(1) For patients with rejection and traditional immunosuppressive therapy, patients should start treatment with Prograf. The recommended starting dose is the same as the level of first immunosuppressive agent.
Tacrolimus injection: The following recommended doses for oral and intravenous administration are only general indicators. The actual dose of the drug should be adjusted according to the needs of individual patients. The recommended dose is only the initial dose, so the treatment should be The clinical judgment was supplemented with monitoring of the concentration of tacrolimus in the blood to adjust the dose.
1. Oral administration: The daily dose is administered in two divided doses. It is best to take capsules on an empty stomach or at least 1 hour before eating or 2-3 hours after eating to achieve maximum absorption. Oral capsules are usually administered continuously to inhibit transplant rejection and have no limitations during treatment.
2. Intravenous administration:
(1) The concentrate for infusion must be diluted with 5% glucose or physiological saline in polyethylene or glass bottles.
Tacrolimus ointment:
1. Adult 0.03% and 0.1% tacrolimus ointment Apply a thin layer of this product on the affected area, gently rub it, and cover it completely, twice a day, until the atopic dermatitis symptoms and signs disappear one week. Encapsulation therapy may promote systemic absorption and its safety has not been evaluated. This product should not be used for external application of package dressings.
2. Children 0.03% tacrolimus ointment Apply a thin layer of this product on the affected area, gently rub it, and cover it completely, twice a day, until a week after the disappearance of atopic dermatitis symptoms and signs. Encapsulation therapy may promote systemic absorption and its safety has not been evaluated. This product should not be used for external application of package dressings.
Tacrolimus capsule:
1. Recommended starting dose for oral administration of Prograf in adults after surgery:
(1) For patients with liver transplantation, the initial oral dose should be 0.1-0.2 mg/kg per day by weight, taken orally twice, and started 6 hours after surgery.
(2) For kidney transplant patients, the initial oral dose should be 0.15-0.3 mg/kg per day by weight, divided into two orally, and the drug should be started within 24 hours after surgery.
2. Rejection that is ineffective against traditional immunosuppressive therapy:
(1) For patients with rejection and traditional immunosuppressive therapy, patients should start treatment with Prograf. The recommended starting dose is the same as the level of first immunosuppressive agent.
(2) The patient is converted from cyclosporine to prograf, and the first dose interval of Prograf is no more than 24 hours.

[Storage]
Tacrolimus Sustained Release Capsules: sealed, stored in a cool, dry place.
Tacrolimus injection: shading, sealed and preserved.
Tacros ointment: sealed.
Tacrolimus capsule: sealed, placed in a cool place.

[Tips] Some of the information on this site comes from the Internet and is only used internally by pharmacists or medical staff. It is not a substitute for doctors to diagnose face to face. Please consult a professional pharmacist for specific medications. Please refer to the actual product manual or the actual product for the product content.

【Product name】IMMUCYST, Immunobladder, TICE BCG

[English common name]Bacillus Calmette-Guerin vaccine

[Chinese common name]BCG

[English name]

[Chinese other name]

[Indications] This product (BCG immunotherapeutic agent) is suitable for intravesical use and treatment of primary recurrent carcinoma in situ (CIS) of the bladder to reduce the frequency of tumor recurrence. It is indicated for the treatment of carcinoma in situ with or without papillary tumors. However, it is not suitable for the treatment of papilloma that occurs alone. This product is also used as a remedy for the bladder to respond to other in situ carcinoma (CIS) treatments. Treatment and prevention of primary or recurrent carcinoma in situ or superficial papilloma after transurethral resection (TA and T1).

[Usage and Dosage] Intravesical treatment and prevention of bladder carcinoma in situ (CIS) should be started 7 to 14 days after biopsy or transurethral resection. In a single dose of 3 vials, this product (BCG immunotherapeutic agent) was administered by intravesical injection once a week for 6 weeks (induction therapy). Each dose (3 bottles of prepared vials) was diluted with 50 ml of bacteria and diluted with preservative-free saline to a total of 53 ml. The urethral catheter is inserted into the bladder under aseptic conditions, guiding the contents of the bladder, and then slowly injecting 50 ml of the suspension of the product by gravity, and then taking out the catheter. During the first hour after perfusion, the patient should be placed in the prone, lying down and lying on the left and right sides for 15 minutes. The patient can then stand but maintain the suspension for 60 minutes for a total of 2 hours. It should be taught to urinate if needed for less time. . At the end of the 2 hours, all patients urinate in a sitting position for safety reasons. Patients should be taught to maintain adequate water. The true number of perfusions required to achieve the optimal response is still unknown. Most responding patients are achieved with 6 to 12 perfusions.

[Storage] The medicine should be placed in a refrigerator of 2 to 8 degrees Celsius (not frozen); if it deteriorates or expires, it can no longer be used.

[Tips] Some of the information on this site comes from the Internet and is only used internally by pharmacists or medical staff. It is not a substitute for doctors to diagnose face to face. Please consult a professional pharmacist for specific medications. Please refer to the actual product manual or the actual product for the product content.

【Product name】Medrol

[English common name]Methylprednisolone

[Chinese common name]Methylprednisolone

[English name]Methylprednisolone, A-Methapred, Adlone-40, Adlone-80

[Chinese other name]A strong dragon, 6a-methylprednisolone, methylprednisolone, methylprednisolone

[Indications] Mainly used for indications of allergic and autoimmune inflammatory diseases.

【Dosage】
1. According to the treatment needs of different diseases, the initial dose of methylprednisolone tablets can be adjusted between 4mg and 48mg of methylprednisolone per day.
(1) Patients with mild symptoms usually receive a lower dose; some patients may require a higher initial dose.
(2) Diseases that are clinically required to be treated with higher doses include multiple sclerosis (200 mg/day), cerebral edema (200-1000 mg/day), and organ transplantation (up to 7 mg/kg/day).
(3) If there is no satisfactory clinical effect after sufficient treatment for a period of time, the methylprednisolone tablet should be discontinued and other suitable treatment methods should be used.
(4) If it is necessary to stop the drug after long-term treatment, it is recommended to reduce the amount by volume, and not to withdraw the drug suddenly.

[Storage] sealed, stored at 15 ° C -25 ° C.

[Tips] Some of the information on this site comes from the Internet and is only used internally by pharmacists or medical staff. It is not a substitute for doctors to diagnose face to face. Please consult a professional pharmacist for specific medications. Please refer to the actual product manual or the actual product for the product content.

【Product name】REMICADE, Remicade

[English common name]Infliximab

[Chinese common name]Infliximab

[English name]

[Chinese other name]

[indications]
Rheumatoid Arthritis
This product is a disease-control anti-rheumatic drug. For patients with moderate to severe active rheumatoid arthritis, this product can be used in combination with methotrexate:
· Reduce symptoms and signs;
· Improve physical function and prevent disability in patients.
Crohn's disease
For patients with moderate to severe active Crohn's disease who are not well received by traditional treatment, this product can be used for:
· Reduce symptoms and signs;
· Achieve and maintain clinical efficacy;
· Promote mucosal healing;
· Improve the quality of life;
· Reduce the amount of corticosteroids or stop using corticosteroids.
Tracheal Crohn's disease
For patients with fistile Crohn's disease, this product can be used for:
Reduce the number of intestinal-cutaneous fistulas and rectal-vaginal fistulas to promote and maintain fistula healing;
· Reduce symptoms and signs;
· Improve the quality of life.
Ankylosing spondylitis
For patients with active ankylosing spondylitis, this product can be used for:
· Alleviate symptoms and signs, including increasing the range of activity;
· Improve physical function;
· Improve the quality of life.
psoriasis
For patients with psoriasis, this product can be used for:
Adult patients with chronic severe plaque psoriasis who require systemic treatment and are ineffective, contraindicated or tolerant to other systems such as cyclosporine, methotrexate or photochemotherapy. This product is intended for use only in patients who are treated under close supervision by a physician and regularly followed up by a physician.

【Dosage】
Usage: intravenous infusion.
Rheumatoid Arthritis
The product was administered 3 mg/kg for the first time, and then the same dose was administered once every 8 weeks after the second week and the sixth week after the first administration and thereafter. This product should be combined with methotrexate. For patients with poor efficacy, consider adjusting the dose to 10 mg/kg and/or adjusting the medication interval to 4 weeks.
Moderate and severe active Crohn's disease, fistula Crohn's disease
The product was administered 5 mg/kg for the first time, and then the same dose was administered once every 8 weeks after the second week and the sixth week after the first administration and thereafter. For patients with poor efficacy, consider adjusting the dose to 10 mg/kg.
Ankylosing spondylitis
The product was administered 5 mg/kg for the first time, and then the same dose was administered once every 6 weeks after the second week and the sixth week after the first administration and thereafter.
User guides
Sterility should be performed.
1. Calculate the dosage and determine the number of bottles used in this product: This product contains 100mg of infliximab per bottle, and calculate the total amount of the solution to be prepared.
2. Dissolve each bottle of medicine with 10 ml of sterile water for injection using a syringe equipped with a 21 gauge (0.8 mm) or smaller needle: remove the flip of the vial, wipe the top of the vial with a medical alcohol swab, and insert the syringe needle into the vial Cover, inject sterile water for injection. If the vacuum in the vial has been destroyed, the bottle cannot be used. Gently rotate the vial to dissolve the powder. Avoid shaking for a long time or with force. Do not oscillate. Foam may appear during the dissolution of the drug. After 5 minutes of storage, the solution should be colorless or light yellow, and the milk is white. Since infliximab is a protein, there may be some translucent particles in the solution. If opaque particles, discoloration or other substances appear in the solution, they cannot be used any more.
3. Dilute the sterile aqueous solution of this product to 250 ml with 0.9% sodium chloride injection: withdraw the same amount of liquid from the 250 ml 0.9% sodium chloride injection bottle or bag as the sterile injectable aqueous solution of this product. The sterile aqueous solution for injection of this product is completely injected into the infusion bottle or bag and gently mixed.
4. The infusion time should not be less than 2 hours: the infusion set should be equipped with a built-in, sterile, pyrogen-free, low protein binding filter (pore size ≤ 1.2 μm). Unused infusions should not be stored for further use.
5. The physical and biochemical compatibility studies of this product in combination with other drugs have not been carried out, and this product should not be infused simultaneously with other drugs.
Products administered parenterally should be visually inspected for the presence of particulate matter or discoloration prior to administration. If opaque particles, discoloration, or other foreign matter are found, the drug may not be used.
Plaque psoriasis
The product was administered 5 mg/kg for the first time, and then the same dose was administered once every 8 weeks after the second week and the sixth week after the first administration and thereafter. If the patient does not respond after week 14 (ie, after 4 doses), the product should not be treated.
Psoriasis patients re-administered
Patients with psoriasis have limited experience with a single administration after 20 weeks, suggesting a reduction in the effectiveness of the product compared to the initial induction therapy and an increase in mild to moderate infusion response.
After relapse of the disease, limited experience with repeated induction therapy showed an increase in infusion response (including severe reactions) compared to 8-week maintenance therapy.
If treatment interruption is maintained, it is not recommended to initiate induction therapy again and should be re-administered according to maintenance therapy.

[Storage]Store at 2-8 °C in the dark.

[Tips] Some of the information on this site comes from the Internet and is only used internally by pharmacists or medical staff. It is not a substitute for doctors to diagnose face to face. Please consult a professional pharmacist for specific medications. Please refer to the actual product manual or the actual product for the product content.